Devonian Health Group, Inc.
DVHGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.34M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16.34 Million |
|---|---|
| Enterprise Value | $15.84 Million |
| Earnings per Share | $-1.76 |
| Beta | 1.26 |
| Outstanding Shares | 2,768,506 |
Return
| Return on Equity | -86.18% |
|---|---|
| Return on Assets | -69.69% |
| Return on Invested Capital | -158.26% |
Valuation & Multiples
| P/E Ratio | -3.76 |
|---|---|
| PEG | 6.3 |
| Price to Sales | - |
| Price to Book Ratio | 2.94 |
| Enterprise Value to Revenue | 6 |
| Enterprise Value to EBIT | -1.42 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Devonian Health Group, Inc.
8 employees
CEO: Andre Boulet
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis an...